DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma

Abstract

Objective

Cuproptosis is a novel cell death pathway that was newly discovered in early 2022. However, cuproptosis is still in its infancy in many respects and warrants further research in hepatocellular carcinoma (HCC). This study aimed to analyze the mechanism of cuprptosis in HCC.

Methods

Herein, the tumor microenvironment infiltration landscape of molecular subtypes was illustrated using GSVA, ssGSEA, TIMER, CIBERSORT, and ESTIMATE algorithms based on the expression profile of cuproptosis-related genes (CRGs) from TCGA and GEO databases. Then, the least absolute shrinkage and selection operator regression method was applied to construct a cuproptosis signature to quantify the cuproptosis profile of HCC. Further, we explored the expression of three hub CRGs in cell lines and clinical patient tissues of HCC by Western blotting, qRT-PCR and immunohistochemistry. Finally, we examined the function of dihydrolipoamide S-acetyltransferase (DLAT) in cuproptosis in HCC by loss-of-function strategy, Western blotting and CCK8 assay.

Results

Three distinct molecular subtypes were identified. Cluster 2 had the greatest infiltration of immune cells with best prognosis. The cuproptosis signature was indicative of tumor subtype, immunity, and prognosis for HCC, and specifically, a low cuproptosis score foreshadowed good prognosis. DLAT was highly expressed in liver cancer cell lines and HCC tissues and positively correlated with clinical stage and grade. We also found that potent copper ionophore elesclomol could induce cuproptosis in a copper-dependent manner. Selective Cu⁺⁺ chelator ammonium tetrathiomolybdate and downregulating DLAT expression by siRNA could effectively inhibit cuproptosis.

Conclusion

Cuproptosis and DLAT as a promising biomarker could help to determine the prognosis of HCC and may offer novel insights for effective treatment.

Keywords

cuproptosis / hepatocellular carcinoma / tumor microenvironment / immune checkpoint / immunotherapy

References

[1] CaoM, LuoX, WuK, et al.. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther, 2021, 6(1): 379

[2] TsvetkovP, CoyS, PetrovaB, et al.. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261

[3] LinS, YangH. Ovarian cancer risk according to circulating zinc and copper concentrations: A metaanalysis and Mendelian randomization study. Clin Nutr, 2021, 40(4): 2464-2468

[4] XiaoY, ChenDI, ZhangX, et al.. Molecular study on copper-mediated tumor proteasome inhibition and cell death. Int J Oncol, 2010, 37(1): 81-87

[5] BlockhuysS, CelauroE, HildesjöC, et al.. Defining the human copper proteome and analysis of its expression variation in cancers. Metallomics, 2017, 9(2): 112-123

[6] IshidaS, AndreuxP, Poitry-YamateC, et al.. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci USA, 2013, 110(48): 19507-19512

[7] GeEJ, BushAI, CasiniA, et al.. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer, 2022, 22(2): 102-113

[8] ZuoXL, ChenJM, ZhouX, et al.. Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res, 2006, 114(1–3): 41-53

[9] LutsenkoS. Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol, 2010, 14(2): 211-217

[10] JiangY, HuoZ, QiX, et al.. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. Nanomedicine (Lond), 2022, 17(5): 303-324

[11] VoliF, ValliE, LerraL, et al.. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. Cancer Res, 2020, 80(19): 4129-4144

[12] LiaoY, ZhaoJ, BulekK, et al.. Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis. Nat Commun, 2020, 11(1): 900

[13] ChanN, WillisA, KornhauserN, et al.. Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. Clin Cancer Res, 2017, 23(3): 666-676

[14] GupteA, MumperRJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev, 2009, 35(1): 32-46

[15] YoshiiJ, YoshijiH, KuriyamaS, et al.. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer, 2001, 94(6): 768-773

[16] ChenD, CuiQC, YangH, et al.. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res, 2006, 66(21): 10425-10433

[17] KarginovaO, WeekleyCM, RaoulA, et al.. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther, 2019, 18(5): 873-885

[18] SungH, FerlayJ, SiegelRL, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249

[19] LuoXY, WuKM, HeXX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res, 2021, 40(1): 172

[20] LvH, LiuX, ZengX, et al.. Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Front Pharmacol, 2022, 13: 930041

[21] ChenQ, WangY, YangL, et al.. PM2.5 promotes NSCLC carcinogenesis through translationally and transcriptionally activating DLAT-mediated glycolysis reprograming. J Exp Clin Cancer Res, 2022, 41(1): 229

[22] GohWQ, OwGS, KuznetsovVA, et al.. DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer-implications in cancer therapy. Am J Transl Res, 2015, 7(6): 1140-1151

[23] StoneS, JiangP, DayananthP, et al.. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res, 1995, 55(14): 2988-2994

[24] SongW, RenJ, XiangR, et al.. Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer. Oncoimmunology, 2021, 10(1): 1987636

[25] KimY, KangJW, KangJ, et al.. Novel deep learning-based survival prediction for oral cancer by analyzing tumor-infiltrating lymphocyte profiles through CIBER-SORT. Oncoimmunology, 2021, 10(1): 1904573

[26] WangT, DaiL, ShenS, et al.. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Front Immunol, 2022, 13: 843408

[27] TangZ, KangB, LiC, et al.. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res, 2019, 47(W1): W556-W560

[28] LiT, FanJ, WangB, et al.. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res, 2017, 77(21): e108-e110

[29] LiSR, BuLL, CaiL. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther, 2022, 7(1): 158

[30] BuccarelliM, D’AlessandrisQ, MatarreseP, et al.. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J Exp Clin Cancer Res, 2021, 40(1): 228

[31] WangpaichitrM, WuC, YouM, et al.. N′,N′-Dimethyl-N′,N′-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers (Basel), 2009, 1(1): 23-38

[32] GaoW, HuangZ, DuanJ, et al.. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol, 2021, 15(12): 3527-3544

[33] O’DayS, EggermontA, Chiarion-SileniV, et al.. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol, 2013, 31(9): 1211-1218